High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Atrial Fibrillation: A Prespecified Analysis of the DANFLU-2 Trial
- PMID: 41295941
- DOI: 10.1016/j.jacc.2025.09.1578
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Atrial Fibrillation: A Prespecified Analysis of the DANFLU-2 Trial
Keywords: atrial fibrillation; high-dose; hospitalizations; influenza; pragmatic; randomized controlled trial; registry; vaccination.
Conflict of interest statement
Funding Support and Author Disclosures The trial was funded by Sanofi. Sanofi participated in the study design and protocol development phase, but had no responsibilities during trial conduct, data collection, or data analysis. Dr Espersen was financed by a research grant from the Danish Cardiovascular Academy, which is funded by the Novo Nordisk Foundation and the Danish Heart Foundation (NNF20SA0067242). Drs Loiacono, Harris, and Dufournet are full-time employees of Sanofi and may own shares or stock options in the company. Dr Larsen has received speaker fees and has served on advisory boards for AstraZeneca, Bavarian Nordic, GSK, Moderna, MSD, Pfizer, Takeda, and Valneva. Dr Clagett has received consulting fees from Amgen, Cardurion, Corvia, Myokardia, and Novartis. Dr Skaarup has served on an advisory board for Sanofi; and has received financial support for congress participation from AstraZeneca. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Puretech Health. Dr Køber has received speaker fees from Novo Nordisk, Novartis, AstraZeneca, Boehringer Ingelheim, and Bayer. Dr Biering-Sørensen has received research grants from Bayer, Novartis, Pfizer, Sanofi Pasteur, GSK, Novo Nordisk, AstraZeneca, Boston Scientific, and GE Healthcare; has received consulting fees from Novo Nordisk, IQVIA, Parexel, Amgen, CSL Seqirus, GSK, and Sanofi Pasteur; and has received lecture fees from AstraZeneca, Bayer, Novartis, Sanofi Pasteur, GE Healthcare, and GSK. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.